DDInter132 DDInter1376
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Atomoxetine {u} (Compound) resembles {v} (Compound) Benzatropine
Atomoxetine {u} (Compound) resembles {v} (Compound) Fenoprofen
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Atomoxetine {u} (Compound) binds {v} (Gene) HTR2C
Atomoxetine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Atomoxetine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Atomoxetine {u} (Compound) downregulates {v} (Gene) FABP5
Atomoxetine {u} (Compound) causes {v} (Side Effect) Depressive symptom
Atomoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Atomoxetine (Compound) resembles Benzatropine (Compound)
Atomoxetine (Compound) resembles Fenoprofen (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Atomoxetine (Compound) binds HTR2C (Gene)
Atomoxetine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Atomoxetine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Atomoxetine (Compound) downregulates FABP5 (Gene)
Atomoxetine (Compound) causes Depressive symptom (Side Effect)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix